Literature DB >> 21889727

Management of side effects of androgen deprivation therapy.

Mathis Grossmann1, Jeffrey D Zajac.   

Abstract

Androgen deprivation therapy (ADT) is a major component of the contemporary management of prostate cancer. ADT's use is increasing rapidly. The side effects of this therapy include loss of bone mass and fractures, increase in fat mass, and worsening of insulin resistance, the metabolic syndrome, diabetes and cardiovascular risk, and anemia and loss of muscle. Neuropsychological and sexual symptoms are common. The impact of these side effects is often overlooked or underestimated in decisions about prostate cancer therapy. This review surveys the data relating to the side effects of ADT and provides recommendations regarding their minimization and management.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889727     DOI: 10.1016/j.ecl.2011.05.004

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  26 in total

1.  COX-2 inhibitors in prostate cancer treatment--hold your horses?

Authors:  Ada S Cheung; Mathis Grossmann
Journal:  Asian J Androl       Date:  2012-05-28       Impact factor: 3.285

Review 2.  Androgen Receptor Structure, Function and Biology: From Bench to Bedside.

Authors:  Rachel A Davey; Mathis Grossmann
Journal:  Clin Biochem Rev       Date:  2016-02

3.  Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia.

Authors:  Chunliu Pan; Neha Jaiswal Agrawal; Yanni Zulia; Shalini Singh; Kai Sha; James L Mohler; Kevin H Eng; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk
Journal:  JCI Insight       Date:  2020-03-26

4.  Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more.

Authors:  Mark Ng Tang Fui; Mathis Grossmann
Journal:  Asian J Androl       Date:  2013-05-20       Impact factor: 3.285

5.  Pitfalls in bone density monitoring in prostate cancer during anti-resorptive treatment.

Authors:  Y-M Cheung; S K Ramchand; M Grossmann
Journal:  Osteoporos Int       Date:  2018-04-17       Impact factor: 4.507

6.  Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison.

Authors:  Kristine A Donovan; Brian D Gonzalez; Ashley M Nelson; Mayer N Fishman; Babu Zachariah; Paul B Jacobsen
Journal:  Psychooncology       Date:  2017-06-27       Impact factor: 3.894

Review 7.  Hematological changes during androgen deprivation therapy.

Authors:  Mathis Grossmann; Jeffrey D Zajac
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

8.  TGFβ Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice.

Authors:  Chunliu Pan; Shalini Singh; Deepak M Sahasrabudhe; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk
Journal:  Endocrinology       Date:  2016-09-09       Impact factor: 4.736

9.  Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Authors:  Ashley M Nelson; Brian D Gonzalez; Heather S L Jim; Julie M Cessna; Steven K Sutton; Brent J Small; Mayer N Fishman; Babu Zachariah; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2016-05-03       Impact factor: 3.603

10.  A systematic review of physical activity-based behaviour change interventions reaching men with prostate cancer.

Authors:  A Finlay; G Wittert; C E Short
Journal:  J Cancer Surviv       Date:  2018-05-16       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.